ALNY's Brezosiran cuts HTT early in trial; pivotal study set for 2027
According to TradingView, phase Ib data show Brezosiran lowered CSF HTT by 60% to 64% at month three; a pivotal trial is slated for 2027.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Early phase Ib results for Brezosiran, reported by TradingView, point to dose-dependent drops in cerebrospinal fluid HTT of 60% to 64% after three months.
The data showed no dose-linked changes in markers of inflammation, neurofilament levels or ventricular size.
A placebo-controlled pivotal study is planned for 2027, subject to alignment with regulators.
why it matters
For ALNY investors this is an early but encouraging step: the HTT effect appears within three months, while decisive evidence will only come after the 2027 trial, and its timing depends on regulators.
market impact
ALNY: encouraging early data supports the pipeline; timing of the next trial depends on regulators
tags
instruments
sources
- ALNY: Brezosiran showed robust early HTT lowering; a pivotal study is planned for 2027 — TradingView, 26 October 2026 at 16:58 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗